Sensex

Nifty

USDINR

GBPINR

EURINR

BSE
NSE

Friday, 16 May 2025 12:00 AM EOD	Adani-Ports1406.80	Asian-Paints2353.15	Axis-Bank1208.30	Bajaj-Finance9166.90	Bajaj-Finserv2033.70	Bharti-Airtel1814.35	Eternal-Ltd245.75	HCL-Technologies1659.75	HDFC-Bank1933.65	Hind-Unilever2381.00	ICICI-Bank1453.65	IndusInd-Bank782.30	Infosys1589.75	ITC435.60	Kotak-Mah-Bank2107.90	Larsen-and-Toubro3605.70	M-and-M3134.55	Maruti-Suzuki12994.00	Nestle-India2410.55	NTPC343.15	Power-Grid-Corpn300.30	Reliance-Industr1456.60	St-Bk-of-India791.85	Sun-PharmaInds1734.95	Tata-Motors730.70	Tata-Steel157.45	TCS3562.95	Tech-Mahindra1616.20	Titan-Company3634.90	UltraTech-Cem11901.50
15 mins delay SENSEX 82,330.59 [-200.15]	0.15 0.01%	22.90 0.98%	0.75 0.06%	-20.60 -0.22%	-8.60 -0.42%	-52.45 -2.81%	3.35 1.38%	-36.30 -2.14%	-0.10 -0.01%	25.85 1.10%	2.80 0.19%	2.00 0.26%	-23.50 -1.46%	3.15 0.73%	1.65 0.08%	-12.35 -0.34%	-9.30 -0.30%	46.70 0.36%	12.55 0.52%	1.20 0.35%	0.70 0.23%	2.80 0.19%	-15.85 -1.96%	-4.70 -0.27%	2.65 0.36%	0.10 0.06%	-17.80 -0.50%	-11.75 -0.72%	-5.70 -0.16%	12.45 0.10%

Hot Pursuit

Scrips, which has significant changes during the market hours.

Lupin gets USFDA nod for Raltegravir tablets

08-May-25 15:42Hrs IST

Raltegravir Tablets are bioequivalent to Isentress HD Tablets, 600 mg, of Merck Sharp & Dohme LLC. Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. The product will be manufactured at Lupin's Nagpur facility in India.

Raltegravir Tablets USP, 600 mg, are indicated for use in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult patients and pediatric patients weighing at least 40 kg.

Raltegravir Tablets USP, 600 mg (Reference Listed Drug: Isentress HD), had estimated annual sales of $34 million in the U.S. for the 12 months ending March 2025, according to IQVIA.

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The company's consolidated net profit jumped 39.5% to Rs 855.16 crore in Q3 FY25 as compared with Rs 613.12 crore in Q4 FY24. Net sales increased 10.6% YoY to Rs 5618.56 crore during the quarter ended 31st March 2025.

The scrip fell 3.12% to end at Rs 2,006.40 on the BSE.

Powered by Capital Market - Live News

Attention Investor :

"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

A Muthoot M George Enterprise